oneCureGEN's research team is currently developing diverse technologies, including the validation of novel targets, discovery of biomarkers, development of innovative anticancer drugs, and drug delivery, which are necessary for the development of first-in-class global anticancer drugs.
Using these technologies, we are currently developing peptides, PROTACs, and small-molecule anticancer agents for targeted therapeutics.